Secretome as neuropathology-targeted intervention of Parkinson's disease

Regen Ther. 2022 Aug 28:21:288-293. doi: 10.1016/j.reth.2022.08.003. eCollection 2022 Dec.

Abstract

Parkinson's disease (PD) is the second most common progressive neurodegenerative disease, characterized by apoptosis of dopaminergic neurons in substansia nigra pars compacta (SNpc) caused by ⍺-synuclein aggregation. The use of secretomes released by medicinal signaling cells (MSCs) is one the promising preventive approaches that target several mechanisms in the neuropathology of PD. Its components target the lack of neurotrophin factors, proteasome dysfunction, oxidative stress, mitochondrial dysfunction, and at last neuroinflammation via several pathways. The complex and obscure pathology of PD induce the difficulty of the search of potential preventive approach for this disease. We described the potential of secretome of MSC as the novel preventive approach for PD, especially by targeting the said major pathogenesis of PD.

Keywords: Mesenchymal stem cell; Molecular targeted therapy; Neurodegenerative disease; Regenerative medicine; Synucleinopathy.

Publication types

  • Review